1270800

フレカイニド 酢酸塩

United States Pharmacopeia (USP) Reference Standard

• 別名: N-（2-ピペリジルメチル）-2,5-ビス-（2,2,2-トリフルオロエトキシ）ベンズアミド 酢酸塩
• 実験式（ヒル表記法）: C₁₇H₂₀F₆N₂O₃ · C₂H₄O₂
• CAS番号: 54143-56-5
• 分子量: 474.39
• MDL番号: MFCD00214290
• UNSPSCコード: 41116107
• PubChem Substance ID: 329749848
• NACRES: NA.24

特性

• グレード: pharmaceutical primary standard
• APIファミリー: flecainide
• メーカー／製品名: USP
• アプリケーション: pharmaceutical (small molecule)
• フォーマット: neat
• 保管温度: 2-8°C
• SMILES記法: CC(O)=O.FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC2CCCCN2
• InChI: 1S/C17H20F6N2O3.C2H4O2/c18-16(19,20)9-27-12-4-5-14(28-10-17(21,22)23)13(7-12)15(26)25-8-11-3-1-2-6-24-11;1-2(3)4/h4-5,7,11,24H,1-3,6,8-10H2,(H,25,26);1H3,(H,3,4)
• InChI Key: RKXNZRPQSOPPRN-UHFFFAOYSA-N
• 遺伝子情報: human ... SCN5A(6331)

詳細

詳細

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

アプリケーション

• Advanced Drug Delivery for Tuberculosis Treatment: Flecainide acetate is integral in developing inhalable porous particles, demonstrating effective lung drug delivery systems for treating tuberculosis. This novel application optimizes the therapeutic index of antituberculosis medications, minimizing systemic side effects while maximizing pulmonary uptake (Campos Pacheco et al., 2024).


• Cardiac Arrhythmia Management: Flecainide acetate, known for its role in arrhythmia management, has been studied for its efficacy following patent foramen ovale closure. The drug′s mechanism as a sodium channel inhibitor makes it a pivotal agent in preventing atrial fibrillation post-surgery, enhancing patient recovery and long-term cardiac health (Apostolos et al., 2024).


• Genetic Research on Arrhythmias: Flecainide acetate is used in genetic models to establish a life-threatening arrhythmia model by screening mutagenized mice. This research aids in identifying genetic predispositions to arrhythmias, paving the way for targeted therapies that modify disease progression and improve patient outcomes (Okabe et al., 2024).


• Electrophysiological Studies: Flecainide acetate′s properties as a class 1C antiarrhythmic agent are utilized in clinical electrophysiology to assess and refine therapeutic strategies for ventricular complex suppression in nonischemic cardiomyopathy. This application underlines its importance in detailed cardiac function studies and therapy optimization (Ruskin et al., 2024).


• Toxicology and Safety Profiling: Research on the potential pitfalls in using hypertonic sodium bicarbonate for treating cardiac toxic drug poisonings, where flecainide acetate is involved, underscores the complexity of managing drug-induced cardiac emergencies. This study provides crucial insights into safer, more effective antidotal therapies (Chan and Buckley, 2024).

アナリシスノート

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

その他情報

Sales restrictions may apply.

安全性情報

• ピクトグラム: GHS08,GHS07
• シグナルワード: Danger
• 危険有害性情報: H302,H315,H319,H335,H360FD
• 注意書き: P202 - P261 - P301 + P312 - P302 + P352 - P305 + P351 + P338 - P308 + P313
• 危険有害性の分類: Acute Tox. 4 Oral - Eye Irrit. 2 - Repr. 1B - Skin Irrit. 2 - STOT SE 3
• ターゲットの組織: Respiratory system
• 保管分類コード: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• WGK: WGK 3
• 引火点(°F): Not applicable
• 引火点(℃): Not applicable